CD274 and neoplasm: In cancer patients, the assessment of PD-L1 status in circulating tumor cells (CTC) and the determination of specific somatic mutations in circulating tumor DNA (ctDNA) represent non-invasive tools acting as predictive markers of the efficacy of the therapeutic response to ICI.